Peanut Allergy Clinical Trial
Official title:
Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
Protocols for Oral Immunotherapy (OIT) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in European and Canadian official guidelines. There has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. This study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05667610 -
Immune-supportive Diet and Gut Permeability in Allergic Children
|
N/A | |
Recruiting |
NCT05440643 -
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
|
Phase 1 | |
Terminated |
NCT03849079 -
Validation of the HYPONUT Product
|
N/A | |
Completed |
NCT02979600 -
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
|
N/A | |
Completed |
NCT01955109 -
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
|
Phase 2 | |
Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
Recruiting |
NCT04415593 -
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
|
N/A | |
Active, not recruiting |
NCT04511494 -
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
|
N/A | |
Active, not recruiting |
NCT04887441 -
Allergology: Information, Data and Knowledge Organization
|
||
Active, not recruiting |
NCT04881773 -
Oral Low Doses Tolerance INduction Study for Peanuts
|
||
Completed |
NCT03682770 -
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
|
Phase 2 | |
Terminated |
NCT03703791 -
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02916446 -
Safety Study of Viaskin Peanut to Treat Peanut Allergy
|
Phase 3 | |
Active, not recruiting |
NCT02402231 -
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
|
Phase 2 | |
Completed |
NCT03337542 -
AR101 Real-World Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT05476497 -
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
|
Phase 1 | |
Completed |
NCT03648320 -
The Grown Up Peanut Immunotherapy Study
|
N/A | |
Completed |
NCT03292484 -
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
|
Phase 3 | |
Completed |
NCT03852342 -
Reactive Doses and Times During Oral Food Challenge to Peanut
|
||
Recruiting |
NCT05138757 -
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
|
Phase 1/Phase 2 |